Drug intelligence / Profile preview

candesartan + amlodipine + atorvastatin (Shinpoong Pharma)

Development stage: Unknown
Lead developer: Shinpoong Pharma
Modality: Small Molecules
Administration: Oral

Overview

SPC5003 is a fixed-dose triple combination therapy developed by Shin Poong Pharmaceutical for the treatment of patients with essential hypertension and comorbid dyslipidemia. The product combines three well-established pharmacological agents: candesartan cilexetil, an angiotensin II receptor blocker (ARB); amlodipine besylate, a dihydropyridine calcium channel blocker (CCB); and atorvastatin calcium, an HMG-CoA reductase inhibitor (statin). By integrating two antihypertensive mechanisms with a lipid-lowering agent into a single daily tablet, SPC5003 aims to simplify complex treatment regimens, enhance patient adherence, and provide comprehensive cardiovascular risk management. The drug is currently in Phase 3 clinical development, with studies evaluating its efficacy and safety compared to dual-combination and monotherapy components.

Other names: candesartan cilexetil + amlodipine besylate + atorvastatin calcium

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on candesartan + amlodipine + atorvastatin (Shinpoong Pharma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on candesartan + amlodipine + atorvastatin (Shinpoong Pharma).

Explore the full profile